TESARO Inc (TSRO) Shares Sold by QVT Financial LP
QVT Financial LP decreased its position in TESARO Inc (NASDAQ:TSRO) by 35.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,605 shares of the biopharmaceutical company’s stock after selling 6,302 shares during the quarter. QVT Financial LP’s holdings in TESARO were worth $962,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Toronto Dominion Bank raised its position in TESARO by 244.6% in the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 1,130 shares during the period. Commonwealth Equity Services Inc purchased a new stake in shares of TESARO during the third quarter worth $222,000. Crossmark Global Holdings Inc. purchased a new stake in shares of TESARO during the third quarter worth $230,000. CIBC Asset Management Inc purchased a new stake in shares of TESARO during the third quarter worth $234,000. Finally, Exane Derivatives increased its position in shares of TESARO by 137.1% during the fourth quarter. Exane Derivatives now owns 1,942 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 1,123 shares during the period.
TESARO Inc (NASDAQ:TSRO) opened at $68.12 on Friday. The company has a debt-to-equity ratio of 1.75, a quick ratio of 4.35 and a current ratio of 4.74. TESARO Inc has a 12 month low of $52.20 and a 12 month high of $179.77.
In other TESARO news, VP Grant C. Bogle sold 1,809 shares of the company’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $54.85, for a total value of $99,223.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Mary Lynne Hedley sold 3,855 shares of the company’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $54.86, for a total transaction of $211,485.30. Following the completion of the transaction, the chief operating officer now owns 16,073 shares of the company’s stock, valued at approximately $881,764.78. The disclosure for this sale can be found here. In the last 90 days, insiders acquired 334,913 shares of company stock valued at $19,083,294 and sold 13,042 shares valued at $760,526. Corporate insiders own 40.50% of the company’s stock.
A number of analysts have recently weighed in on TSRO shares. Citigroup reaffirmed a “buy” rating and set a $135.00 price objective (down previously from $216.00) on shares of TESARO in a research report on Wednesday, December 20th. Argus set a $154.00 price objective on TESARO and gave the stock a “buy” rating in a research report on Tuesday, November 28th. HC Wainwright reaffirmed a “buy” rating and set a $158.00 price objective on shares of TESARO in a research report on Monday, November 20th. Cann reaffirmed a “buy” rating and set a $122.00 price objective (down previously from $199.00) on shares of TESARO in a research report on Tuesday, February 27th. Finally, Barclays cut their price objective on TESARO from $135.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 28th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. TESARO presently has an average rating of “Buy” and an average price target of $133.39.
COPYRIGHT VIOLATION WARNING: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/03/11/tesaro-inc-tsro-shares-sold-by-qvt-financial-lp.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO Inc (NASDAQ:TSRO).
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.